Is a complete ADXN research report available?

No complete published report is available for Addex Therapeutics Ltd (ADXN) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Addex Therapeutics Ltd (ADXN)

NASDAQ: ADXN · USD

$5.89

+0.00 (0.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first ADXN analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	6.3M
Revenue (ttm)	136.5K
Net income (ttm)	-8.7M
EPS (ttm)	-$0.08
Shares out	119.3M
Volume	187
Beta	1.99

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 136.5K
Net income (ttm): -8.7M
EPS (ttm): -$0.08
Market cap: 6.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All ADXN indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

CHF

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001574232
Company name	Addex Therapeutics Ltd
Country	Switzerland
Country code	US
Cusip	00654J206
Employees	3
Employees Change	1%
Employees Change Percent	50
Enterprise value	$5.3M
Exchange	NASDAQ
Financial currency	CHF
First seen	2026-05-09
Industry	Biotechnology
Isin	US00654J2069
Last refreshed	2026-07-25
Market cap	$6.3M
Market cap category	Nano-Cap
Price	$5.89
Price currency	USD
Rev Per Employee	45,502.67x
Sector	Healthcare
Sector PE	44.87
Sector PE Fwd	23.76
Sic	2834
Symbol	ADXN
Website	https://www.addextherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-138.28%
EV/Sales	38.55x
FCF yield	-45.49%
P/B ratio	1.53x
P/S ratio	46.02x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-2,455.03%
EBITDA Margin	-2,440.26%
Gross Profit	$-551,312
Net Income	$-8.7M
Net Income Growth Years	0%
Pretax Margin	-6,467.34%
Profit Per Employee	$-2.9M
ROA	-23.59
Roa5y	-30.59
ROCE	-74.49
ROE	-122.3
Roe5y	-92.85
ROIC	-28.66

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-27.53%
Cagr3y	-19.98%
Cagr5y	-49.97%
EPS Growth Years	0
Revenue Growth	-55.52x
Revenue Growth Q	-89.18x
Revenue Growth Years	0x
Revenue Growth3 Y	-59.94x
Revenue Growth5 Y	-50.93x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.02
Assets	$5.9M
Cash	$1.2M
Current Assets	$1.5M
Current Liabilities	$1.5M
Debt	$127,498
Debt Equity	$0.03
Equity	$4.1M
Interest Coverage	-931.4
Liabilities	$1.8M
Long Term Assets	$4.5M
Long Term Liabilities	$342,289
Net Cash	$1M
Net Cash By Market Cap	$16.53
Net Cash Growth	-70.1%
Net Debt Equity	$-0.25
Tangible Book Value	$4.1M
Tangible Book Value Per Share	$0.03
WACC	14.96

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.97
Net Working Capital	$-1.1M
Quick ratio	0.79
Working Capital	$-40,592
Working Capital Turnover	$0.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-14.34%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-27.52%
200-day SMA	7.58
3Y total return	-48.76%
50-day SMA	6.38
50-day SMA vs 200-day SMA	50under200
5Y total return	-96.87%
All Time High	750.4
All Time High Change	-99.22%
All Time High Date	2020-08-07
All Time Low	5
All Time Low Change	17.7%
All Time Low Date	2023-12-15
ATR	0.39
Beta	1.99
Ch YTD	-23.77
High	5.94
High52	12.05
High52 Date	2025-09-12
High52ch	-51.16%
Low	5.32
Low52	5.32
Low52 Date	2026-07-24
Low52ch	8.78%
Ma50ch	-7.79%
Price vs 200-day SMA	-22.32%
RSI	46.98
RSI Monthly	34.57
RSI Weekly	40.05
Sharpe ratio	0.01x
Sortino ratio	0.07
Total Return	-14.34%
Tr YTD	-23.77
Tr1m	-5.08%
Tr1w	-4.85%
Tr3m	-16.29%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-3.4M
Operating margin	-2,455

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	97,064,535%
Float Percent	81.35%
Net Borrowing	-8,635.8
Shares Insiders	18.65%
Shares Institutions	1.09%
Shares Out	119,318,896
Shares Qo Q	0.55%
Shares Yo Y	14.34%
Short Ratio	0.3
Short Shares	0.14

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-2.9M
Average Volume	3,070.55x
Bv Per Share	0.03
Ch1m	-5.08
Ch1w	-4.85
Ch1y	-27.52
Ch3m	-16.29
Ch3y	-48.76
Ch5y	-96.87
Ch6m	-29.1
Change	0%
Change From Open	5.47
Close	0
Depreciation Amortization	-1,940.5
Dollar Volume	1,100.5
Earnings Date	2026-06-25
Earnings Time	bmo
EBIT	$-3.3M
EBITDA	$-3.3M
EPS	$-0.08
F Score	1
FCF	$-2.9M
FCF EV Yield	-54.3x
FCF Per Share	$-0.02
Financing CF	1,435,319
Fiscal Year End	December
Founded	2,002
Investing CF	-848,610
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-06-25
Last Report Date	2026-03-31
Last Split Date	2023-10-23
Last Split Type	Reverse
Last10k Filing Date	2026-05-15
Ma150	7.07
Ma150ch	-16.74%
Ma20	5.97
Ma20ch	-1.37%
Net CF	-2,356,669
Next Earnings Date	2026-09-29
Open	5.58
Optionable	No
Position In Range	91.13
Ppne	123,959.5
Price Date	2026-07-24
Ptbv Ratio	1.53
Relative Volume	0.06x
Revenue	136,508x
SBC By Revenue	62.84x
Share Based Comp	85,785
Tr6m	-29.1%
Volume	187
Z Score	-105.9

Addex Therapeutics Ltd (ADXN)

Coverage state: Market snapshot only — no published research

Generate the first ADXN analysis

Price

Financial snapshot

Fair-value bridge

Latest news · ADXN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ADXN indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ADXN

Frequently asked questions